Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Teladoc Health is expanding its Comprehensive Weight Care program with a new employer contribution model for GLP-1 medications. Employers can now set a fixed per-fill contribution toward drugs from Eli Lilly and Novo Nordisk, with employees covering the rest. New two-year outcome data from nearly 23,000 members shows nearly half achieved clinically meaningful weight loss.
Teladoc Health is shaking up how employers handle GLP-1 costs with a new flexible contribution model built into its Comprehensive Weight Care program. Rather than routing medications through traditional pharmacy benefit designs, employers can now set a fixed payment per employee per fill — covering drugs from Eli Lilly and Novo Nordisk — while employees pay the remaining balance. The program bundles medication access with licensed professional support, personalized lifestyle coaching, and AI-enabled food logging, with Teladoc managing eligibility, invoicing, and audit-ready claims documentation.
Employers can also tie their contributions to member engagement metrics like food logging and regular weigh-ins, adding an incentive layer to the benefit. The offering is available now, with the first contracted clients set to launch programs on January 1, 2027.
By the Numbers:
Why it matters: With GLP-1 medications carrying steep price tags, employers have been searching for sustainable ways to offer this benefit without blowing up their healthcare budgets. Teladoc's model offers a middle ground — giving employees access to FDA-approved obesity treatments while giving employers cost predictability and transparency.